** J.P. Morgan upgrades gene therapy maker bluebird bio BLUE.O to "neutral" from "underweight" rating, citing co's announcement that it would be taken private
** Brokerage expects co's privatization to take place within 1H25
** BLUE says it will be taken private by Carlyle CG.O and SK Capital Partners
** 1 of 8 brokerages rate BLUE stock "buy", 7 "hold"; their median PT is $10 - LSEG data
** As of last close, stock down ~51.1% YTD
(Reporting by Prakhar Srivastava in Bengaluru)
((Prakhar.srivastava2@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。